CAS: 1061358-78-8; 2-Chloro-5-(Trifluoromethyl)Pyridin-4-Amine
该化合物是一种卤代丙烯衍生物,含有氯和三氟甲基替代物,增强了其在有机合成中的再活动性和实用性.电子退出三氟甲基组和核生殖性动物运动的存在使它成为构建复杂的三环化合物的多功能中间体.其结构特征在制药和农用化学应用中特别宝贵,因为这种元素有助于改善代谢稳定性和结合.该化合物定义明确的再活动特征允许选择性功能化,使其能够用于交叉相交反应,核循环替代和其他转化.高纯度和持续的质量确保了研究和工业流程的可靠性能.
- 英文名称2-Chloro-5-(Trifluoromethyl)Pyridin-4-Amine
- 中文名称2-氯-5-(三氟甲基)吡啶-4-胺
- IUPAC名称2-chloro-5-(trifluoromethyl)pyridin-4-amine
- 其它别名2-氯-5-(三氟甲基)吡啶-4-胺; 6-氯-3-三氟甲基吡啶-4-胺; 2-Chloro-5-Trifluoromethyl-Pyridin-4-Ylamine
- CAS编号1061358-78-8
- MFCD编号:MFCD16658126
- EINECS号:100-609-2
- 分子式:C6H4ClF3N2分子量:196.56
- 产品CID: 102620
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物
相似化合物
1956363-89-5 1807167-88-9 1805959-34-5物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
2-氯-5-三氟甲基吡啶 2-Chloro-5-Trifluoromethylpyridine 52334-81-32-氯-5-三氟甲基-4-碘吡啶 2-Chloro-4-Iodo-5-(Trifluoromethyl)Pyridine 505084-55-9
合成工艺路线路线简述
📜2-氯-5-三氟甲基吡啶-4-甲酸置于叠氮磷酸二苯酯,三乙胺,三氟乙酸体系中,用 二氯甲烷,甲苯 用作溶剂,化学反应 10.0H,反应生成2-氯-5-(三氟甲基)吡啶-4-胺
参考文献:Multiparameter Lead Optimization To Give An Oral Checkpoint Kinase 1 (Chk1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-Ylmethyl)Amino)-5-(Trifluoromethyl)Pyridin-2-yl)Amino)Pyrazine-2-Carbonitrile (Cct245737)
标题:Multiparameter Lead Optimization To Give An Oral Checkpoint Kinase 1 (Chk1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-Ylmethyl)Amino)-5-(Trifluoromethyl)Pyridin-2-yl)Amino)Pyrazine-2-Carbonitrile (Cct245737)
摘要:Multiparameter Optimization Of A Series Of 5((4-Aminopyridin-2-yl)Amino)Pyrazine-Carbonitriles Resulted In The Identification Of A Potent And Selective Oral Chk1 Preclinical Development Candidate With In Vivo Efficacy As A Potentiator Of Deoxyribonucleic Acid (Dna) Damaging Chemotherapy And As A Single Agent. Cellular Mechanism Of Action Assays Were Used To Give An Integrated Assessment Of Compound Selectivity During Optimization Resulting In A Highly Chk1 Selective Adenosine Triphosphate (Atp) Competitive Inhibitor. A Single Substituent Vector Directed Away From The Chk1 Kinase Active Site Was Unexpectedly Found To Drive The Selective Cellular Efficacy Of The Compounds. Both Chk1 Potency And Off-Target Human Ether-A-Go-Go-Related Gene (Herg) Ion Channel Inhibition Were Dependent On Lipophilicity And Basicity In This Series. Optimization Of Chk1 Cellular Potency And In Vivo Pharmacokinetic Pharmacodynamic (Pk-Pd) Properties Gave A Compound With Low Predicted Doses And Exposures In Humans Which Mitigated The Residual Weak In Vitro Herg Inhibition.
Doi:10.1021/acs.Jmedchem.5B01938
专利信息
专利号:US-2023150994-A1
优先权日:2020-04-07
标 题:Methods for synthesis of chk1 inhibitors
发明人：SCHWAEBE MICHAEL; ROSNER THORSTEN; ZHAO DALIAN; MILLER ROSS; DULINA RICH; HUMORA MICHAEL; GOTTSCHLING STEPHEN E
权利人:SIERRA ONCOLOGY INC
摘要:The present technology relates to processes, compounds, compositions, and methods useful for coupling reactions. Also, the present disclosure provides for novel intermediates, compositions of matter, and processes relating to the Chk1 inhibitor, SRA737.
专利号:TW-202204348-A
优先权日:2020-04-07
标 题:Methods for synthesis of chk1 inhibitors
专利号:EP-4132922-A1
优先权日:2020-04-07
标 题 :Methods for synthesis of chk1 inhibitors
专利号:WO-2021207210-A1
优先权日:2020-04-07
标 题 :Methods for synthesis of chk1 inhibitors
